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Circulation: Arrhythmia and Electrophysiology
ORIGINAL ARTICLE

Effect of Chloroquine, Hydroxychloroquine, and
Azithromycin on the Corrected QT Interval in
Patients With SARS-CoV-2 Infection
Moussa Saleh , MD; James Gabriels , MD; David Chang , MD; Beom Soo Kim, MD; Amtul Mansoor , MD;
Eitezaz Mahmood, MD; Parth Makker , MD; Haisam Ismail, MD; Bruce Goldner , MD; Jonathan Willner, MD;
Stuart Beldner, MD; Raman Mitra , MD, PHD; Roy John, MBBS, PHD; Jason Chinitz, MD; Nicholas Skipitaris , MD;
Stavros Mountantonakis, MD; Laurence M. Epstein , MD
BACKGROUND: The novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is responsible for the global coronavirus
disease 2019 pandemic. Small studies have shown a potential benefit of chloroquine/hydroxychloroquine±azithromycin for
the treatment of coronavirus disease 2019. Use of these medications alone, or in combination, can lead to a prolongation of
the QT interval, possibly increasing the risk of Torsade de pointes and sudden cardiac death.
METHODS: Hospitalized patients treated with chloroquine/hydroxychloroquine±azithromycin from March 1 to the 23 at 3 hospitals
within the Northwell Health system were included in this prospective, observational study. Serial assessments of the QT interval
were performed. The primary outcome was QT prolongation resulting in Torsade de pointes. Secondary outcomes included QT
prolongation, the need to prematurely discontinue any of the medications due to QT prolongation, and arrhythmogenic death.
RESULTS: Two hundred one patients were treated for coronavirus disease 2019 with chloroquine/hydroxychloroquine. Ten
patients (5.0%) received chloroquine, 191 (95.0%) received hydroxychloroquine, and 119 (59.2%) also received azithromycin.
The primary outcome of torsade de pointes was not observed in the entire population. Baseline corrected QT interval
intervals did not differ between patients treated with chloroquine/hydroxychloroquine (monotherapy group) versus those
treated with combination group (chloroquine/hydroxychloroquine and azithromycin; 440.6±24.9 versus 439.9±24.7 ms,
P=0.834). The maximum corrected QT interval during treatment was significantly longer in the combination group versus the
monotherapy group (470.4±45.0 ms versus 453.3±37.0 ms, P=0.004). Seven patients (3.5%) required discontinuation of
these medications due to corrected QT interval prolongation. No arrhythmogenic deaths were reported.
CONCLUSIONS: In the largest reported cohort of coronavirus disease 2019 patients to date treated with chloroquine/hydroxyc
hloroquine±azithromycin, no instances of Torsade de pointes, or arrhythmogenic death were reported. Although use of these
medications resulted in QT prolongation, clinicians seldomly needed to discontinue therapy. Further study of the need for QT
interval monitoring is needed before final recommendations can be made.
VISUAL OVERVIEW: A visual overview is available for this article.
Key Words: azithromycin ◼ chloroquine ◼ COVID-19 ◼ hydroxychloroquine ◼ pandemic ◼ QT prolongation

I

n December of 2019, reports of an unknown pneumonia not responsive to traditional treatments emerged in
Wuhan, China. The pathogen, which came to be identified as the severe acute respiratory syndrome coronavirus 2

(SARS-CoV-2), is a novel coronavirus that is now known to
be responsible for the coronavirus disease 2019 (COVID19) illness. Since then, the virus has spread internationally
infecting ≈1 million individuals and resulting in >50 000
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WHAT IS KNOWN?
• The antimalaria drugs chloroquine and hydroxychloroquine and the commonly used macrolide
antibiotic azithromycin are all known to increase the
corrected QT interval.
• A corrected QT interval >500 ms increases the risk
of torsade de pointes by 2- to 3-fold. Other risk factors include drug interactions affecting drug serum
levels, concomitant use of QT prolonging agents,
female gender, structural heart disease, genetic
polymorphisms, electrolyte disturbances, bradycardia, and hepatic disease.

WHAT THE STUDY ADDS?
• In hospitalized COVID-19 patients, the use of
chloroquine/hydroxychloroquine and azithromycin
resulted in a significantly greater increase in the corrected QT interval when compared with monotherapy with either chloroquine or hydroxychloroquine.
• Although patients experienced corrected QT interval prolongation, especially when combination
therapy was used, the risk of arrhythmic death and
torsade de pointes were not increased.
• Though
the
efficacy
of
chloroquine/
hydroxychloroquine±azithromycin in patients with
coronavirus disease 2019 (COVID-19) is unproven,
the arrhythmic risk appears to be low and may not
warrant monitoring in most hospitalized patients.

Nonstandard Abbreviations and Acronyms
COVID-19
coronavirus disease 2019
hERG		
human ether-à-go-go related gene
MCOT		
Mobile Cardiac Outpatient Telemetry
SARS-CoV-2	severe acute respiratory syndrome
coronavirus 2
TdP		
torsade de pointes

deaths. COVID-19 was declared a public health emergency
of international concern on January 30, 20201. Although
strong data supporting any specific therapy has been lacking, several pharmacological intervention strategies have
been proposed for the management of COVID-19 in hopes
of decreasing morbidity and mortality related to the illness.
One such therapy currently under study in humans is the use
of chloroquine or hydroxychloroquine. Chloroquine, a medication commonly used to treat malaria, has been shown to
inhibit viral infection by changing the endosomal pH that is
required for viral-cell fusion as well as interfering with the
glycosylation of cellular receptors of SARS-CoV.2 Compared
with chloroquine, hydroxychloroquine has been shown in
vitro to have higher inhibition against SARS-CoV-2.3 These
limited studies have resulted in a surge in the use of chloroquine or hydroxychloroquine with and without azithromycin

in patients requiring inpatient care for COVID-19. Although
many are hopeful that these inexpensive and readily available medications may be the key to decreasing mortality in
this pandemic, as of the writing of this article, no such data
exists. A notable concern is the association of QT prolongation and Torsade de pointes (TdP) with these medications
when individually prescribed, and the increased risk when
they are administered together, especially in patients with
hepatic disease or renal failure. To evaluate the arrhythmic
safety of chloroquine/hydroxychloroquine±azithromycin, we
conducted this prospective evaluation in adult patients hospitalized with COVID-19.

METHODS
To minimize the possibility of unintentionally sharing information that can be used to reidentify private information, a subset of the data generated, and the analytical methods used for
this study are available from the corresponding author to other
researchers upon reasonable request. This study was approved
by the Institutional Review Board of Northwell Health, which
waived the requirement for individual informed consent.
From the start of the outbreak until April 4, 2020, 3180
patients have received combination hydroxychloroquine and
azithromycin, and 1181 patients received hydroxychloroquine
alone for the treatment of COVID-19 in 14 hospitals of the New
York State Northwell Health system. The present study is an
in-depth prospective, observational study from 3 of the hospitals. All hospitalized patients >18 years of age with polymerase
chain reaction confirmed COVID-19 illness treated with chloroquine/hydroxychloroquine±azithromycin were identified from
March 1 to March 23. The decision to treat with chloroquine/
hydroxychloroquine±azithromycin was based on the clinical
decision of the admitting physician and predescribed healthcare
system guidelines. Healthcare system criteria for the use of
chloroquine/hydroxychloroquine±azithromycin therapy placed
on March 1 were as follows: confirmed Covid-19 polymerase
chain reaction testing or high suspicion of Covid-19 with test
pending; acute respiratory distress syndrome or severe illness
characterized by systemic inflammatory response syndrome
criteria; or clinician’s judgment that the patient is likely to progress to acute respiratory distress syndrome or severe illness in
the next 6 hours. Patients not meeting the criteria for therapy
were excluded from the study. Patients chronically on hydroxychloroquine for autoimmune diseases, such as lupus, those with
a documented hypersensitivity to any of the agents, and any
patient that refused the therapies were excluded from the study.
Demographics, inpatient medication lists, values from the
baseline ECGs including QRS duration, QRS morphology, and QT
interval duration were collected on all patients before initiation of
therapy. Inpatient medication orders were reviewed daily and any
concomitant QT-prolonging agent usage was identified. Twice
daily ECGs, except for patients that received a Mobile Cardiac
Outpatient Telemetry (MCOT) Patch (BioTelemetry, Malvern, PA),
were obtained to assess the corrected QT interval (QTc). Given
the large number of COVID-19 patients admitted throughout the
health system and the limited amount of telemetry beds available,
the MCOT patches were used to monitor for both QT prolongation and for arrhythmias in patients on nontelemetry units. MCOT
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patches were preprogrammed to transmit twice daily telemetry
strips for QT interval measurements. Telemetry or MCOT Patch
urgent alerts were reviewed for all patients and any cardiac
arrhythmias were documented. Premature discontinuation of any
of the medications due to QT prolongation was also noted. All
QT intervals obtained from an ECG or MCOT patch were manually measured by a physician on the research team. Lead II was
utilized for the measurement of the QT interval on ECG. If the
T-wave could not easily be measured in lead II, leads V6, or I were
alternatively used. The end of the T-wave was defined as the tangent drawn from the steepest last limb of the T-wave to its intersection with the baseline. If a baseline BBB was present, the J-T
interval was measured and 120 ms was added to obtain the QT
interval duration. Bazett formula was used to calculate the corrected QT interval. Baseline QT interval measurements obtained
from the MCOT patch were compared with that of the baseline
ECG utilizing lead I, as the MCOT patch provides a lead I strip,
to ensure accuracy. Serial ECGs were not obtained on MCOT
patients to decrease staff exposure. Given the observational
nature of the study, members of the research team measuring the
QT interval were not blinded to the patient information or course.
All telemetry, ECG, and MCOT patch monitoring findings, and QT
interval measurements were adjudicated by a senior board-certified cardiac electrophysiologist and a cardiac electrophysiology
fellow board-certified in cardiovascular disease.

OUTCOME MEASURES
The primary clinical outcome of the study was QT prolongation resulting in TdP. Secondary outcomes included
QT prolongation and QT prolongation that resulted in the
need to prematurely terminate chloroquine, hydroxychloroquine, or azithromycin as well as arrhythmogenic death.

STATISTICAL ANALYSIS
As this was a prospective, observational study without a
specific control population, only a basic statistical analysis was utilized. Continuous variables were reported as
the mean±SD and categorical variables were reported
as numerical values and percentages. The Welch t test
was used to compare ECG changes during treatment
with the patients’ baseline ECGs. A multivariable linear
regression analysis was performed to test the impact of
monotherapy versus combination therapy, and gender
along with the interaction between the 2 on the outcome
of change in QTc. Fisher exact test was used to compare
the number of patients with a QTc >500 ms in the monotherapy versus combination groups. The SAS Version 9.4
(Cary, NC) statistical software was used for the analysis.

RESULTS
Between March 1st and March 23, there were 201
patients that were treated for COVID-19 with either
chloroquine or hydroxychloroquine at 3 hospitals in the
Northwell Health system. A minority of these patients

COVID-19 Therapy Effect on the QTc

(10, 5.0%) received chloroquine. Of the 201 patients on
either chloroquine or hydroxychloroquine, 119 (59.2%)
also received azithromycin. The treatment regimens for
these medications were as follows: chloroquine 500 mg
by mouth twice daily for 1 day followed by 500 mg by
mouth once daily for 4 days, hydroxychloroquine 400 mg
by mouth twice daily for 1 day followed by 200 mg by
mouth twice daily for 4 days, and azithromycin 500 mg
by mouth or intravenous daily for 5 days. The average
age of the cohort was 58.5±9.1 and 115 (57.2%) were
male patients. Complete demographics are displayed in
Table 1, and details regarding inpatient medication usage
are outlined in Table 2.
A baseline ECG was performed before initiating therapy for COVID-19 for all patients. A majority of patients
were in sinus rhythm (177, 88.1%) with baseline heart rate
of 80.5±17.7 beats per minute. The mean QRS duration
for the population at baseline was 92.8±19.0 ms with 46
patients (22.9%) having an intraventricular conduction
delay, incomplete, or complete right bundle branch block,
left bundle branch block, or a ventricular paced rhythm.
Serial ECGs were used to monitor QTc intervals for 84
patients, and 117 patients (58.2%) were monitored with
an MCOT patch. The baseline QTc for the entire cohort
was 439.5±24.8 ms and 8 patients (4.0%) had a baseline QTc >500 ms. The average maximum QTc during
treatment for the entire cohort was 463.3±42.6 ms and
the post-treatment QTc was 454.8±40.1 ms. The average increase in the QTc after the 5-day course treatment
was 19.33±42.1 ms (Table 3).
The baseline QTc intervals for the monotherapy group
were 438.9±25.0 ms and for the combination therapy
group was 439.9±24.7 ms (P=0.79). The maximum QTc
during treatment was significantly shorter in patients
Table 1.

Baseline Demographics

Characteristic
Age, y
Male sex
Body mass index, kg/m2

N=201
58.5±9.1
115 (57.2%)
28.2±2.8

Hypertension

121 (60.2%)

Hyperlipidemia

84 (41.8%)

Diabetes mellitus

65 (32.3%)

Atrial fibrillation

14 (7.0%)

Coronary artery disease

23 (11.4%)

Chronic obstructive pulmonary disease/asthma

30 (14.9%)

Chronic kidney disease ≥stage III

10 (5.0%)

Ejection fraction, %

61.9±5.7*

Heart failure

15 (7.5%)

Prior permanent pacemaker/automated internal
cardioverter-defibrillator

3 (1.5%)

Values listed are represented as means±SDs for continuous variables and
numbers (percentages) for categorical variables.
*Data for ejection fraction, including echocardiograms performed within the
last 6 months, was only available for 41 patients (20.4%).
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Table 2.

COVID-19 Therapy Effect on the QTc

Inpatient Medication Usage

Medication
Hydroxychloroquine
Chloroquine

N=201
191 (95.0%)
10 (5.0%)

ECG Characteristics

N=201

Sinus rhythm

119 (59.2%)

P Value

177 (88.1%)

Atrial fibrillation/flutter

Azithromycin
Total

Table 3. Electrocardiographic Characteristics of the
Study Cohort

14 (7.0%)

Baseline heart rate

80.5±17.7
92.8±19.0

1 dose

26 (12.9%)

Baseline QRS

2–4 doses

46 (22.9%)

Baseline QTc

439.5±24.8

–

47 (23.4%)

Max QTc

463.3±42.6

<0.05

34 (16.9%)

Max QTc—baseline QTc

23.8±35.5

QRS duration

94.9±19.2

5 doses
Beta blocker/nondihydropyridine calcium channel
blocker
Antiarrhythmic medications

3 (1.5%)

QRS duration—baseline QRS

2.2±9.6

Antiplatelets

28 (13.9%)

Final QTc

Oral anticoagulants

12 (6.0%)

Final QTc—baseline QTc

15.4±35.4

QRS duration

95.9±20.2

QRS duration—baseline QRS

3.0±10.5

Other QT prolonging agents*

81 (40.3%)

Values listed are represented as numbers (percentages) for categorical
variables.
*Albuterol, alprazolam, amiodarone, amitriptyline, aripiprazole, citalopram,
chlorpromazine, ciprofloxacin, clozapine, cyclobenzaprine, dexmedetomidine,
diphenhydramine, donepezil, dronedarone, escitalopram, flecainide, furosemide,
fluconazole, haloperidol, levetiracetam, levofloxacin, lithium, metoclopramide,
mirtazapine,
norepinephrine,
olanzapine,
ondansetron,
pantoprazole,
phenobarbital, quetiapine, risperidone, venlafaxine, ziprasidone

treated with chloroquine/hydroxychloroquine monotherapy when compared with patients treated with a combination of either of these medications and azithromycin
(453.3±37.0 versus 470.4±45.0 ms, P=0.004; Table 4).
Additionally, there were no statistically significant effects
of gender (P=0.091) or an interaction between the effects
of gender and medications on the difference between
the Maximum QTc and the baseline QTc (P=0.93). The
overall trajectory of QTc change is represented in Figure 1. The number of patients with a peak QTc >500
ms was 7 (8.6%) in the monotherapy group versus 11
(9.2%) in the combination therapy group (P=1.00) (Figure 2). Further details regarding these patients can be
found in Table 5.
In addition to QT prolongation, there were 17 instances
of new-onset atrial fibrillation that were discovered either
on telemetry or an MCOT patch. Seven patients had
monomorphic nonsustained ventricular tachycardia, and
1 patient had sustained, hemodynamically stable, monomorphic ventricular tachycardia in the setting of likely viral
myocarditis (Table 6). The primary outcome of QT prolongation leading to TdP was not observed in the entire
population. Arrhythmogenic death was also not observed
in the entire cohort. The secondary outcome involving the
need to discontinue hydroxychloroquine due to QT prolongation occurred in 7 (3.5%) patients with average QTc of
504.4±39.5 ms. Details regarding these patients can be
found in Tables 7 and 8. The trajectory of their QTc change
is represented in Figure 3. A complete list of arrhythmic
events and interventions is listed in Table 9. Following
the development and implementation of the Northwell
flow chart to minimize TdP in COVID-19 inpatients on

454.8±40.1

<0.05

Values listed are represented as means±SDs for continuous variables. P
values to assess ECG changes to the baseline ECG. QTc indicates corrected
QT interval.

hydroxychloroquine/azithromycin, lidocaine was used to
facilitate continuation of hydroxychloroquine in 2 other
patients.4 The first patient’s QTc increased from baseline
of 458 to 594 ms after receiving hydroxychloroquine 400
mg for 2 doses followed by 200 mg for 3 doses and 2
doses of intravenous azithromycin 500 mg. The patient
was given a single dose of intravenous lidocaine 100 mg,
which improved QTc to 479 ms. Azithromycin was discontinued at this time while hydroxychloroquine 200 mg twice
daily was continued for the full 5-day course. Of note, this
patient was given a dose of intravenous amiodarone 150
mg 2 days before reaching the peak QTc during a rapid
Table 4. Comparison of QTc Measurement in HCQ Cohort
vs HCQ and AZM Cohort
QTc
QTc
Measurements Measurements
in Patients
in Patients
Treated With
Treated With
HCQ/CQ
HCQ/CQ and
(N=82)
AZM (N=119) P Value
Baseline QTc

438.9±25.0

439.9±24.7

0.79
0.85

Baseline QRS

92.0±15.5

93.0±19.8

Max QTc

453.3±37.0

470.4±45.0

0.004

Max QTc—baseline QTc

14.4±25.0

30.4±40.2

<0.001

QRS duration

91.9±15.6

95.6±20.0

0.48

QRS duration—baseline QRS

−0.1±6.14

2.7±10.2

0.21

7

11

1.00

QTc >500 (no. of patients)
Final QTc

444.7±34.2

462.0±42.4

Final QTc—baseline QTc

6.0±25.0

22.0±40.1

<0.001

0.002

QRS duration

91.9±13.1

96.7±21.4

0.30

QRS duration—baseline QRS

−0.2±8.5

3.7±10.8

0.18

Values listed are represented as means±SDs for continuous variables.
AZM indicates azithromycin; CQ, chloroquine; HCQ, hydroxychloroquine; QTc,
corrected QT; and Max, maximum.
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Figure 1. Trajectory of corrected QT
interval (QTc) change in 201 patients
receiving hydroxychloroquine±azith
romycin.
Change in QTc was seen starting on day
2 of therapy with max QTc being reached
on day 4 by the majority of patients.

response for atrial fibrillation and acute hypoxic respiratory failure that required intubation. Two days after finishing the course of hydroxychloroquine, the QTc prolonged
to 601 ms. Of note, the patient was receiving intravenous
furosemide and pantoprazole, which may have contributed to the QTc prolongation. The patient appropriately
responded to another dose of intravenous lidocaine. The
subsequent QTc improved to 551 mg and normalized to
<500 ms on subsequent ECGs. The second patient’s QTc
increased from 456 ms to 620 ms after receiving 1 dose
of hydroxychloroquine. She was given a dose of intravenous lidocaine 100 mg, which improved the QTc to 550
ms. This patient went on to complete the 5-day course of
hydroxychloroquine with no further prolongation of QTc.

DISCUSSION
The main findings of this study were (1) the use of chloroquine/hydroxychloroquine and azithromycin led to a
significantly greater increase in the corrected QT interval
when compared to monotherapy with either chloroquine
or hydroxychloroquine, (2) prolongation of the QTc only
led to premature discontinuation of these medications in

3.5% of patients, and (3) there were no instances of the
primary end point of TdP in the entire cohort.
The SARS-CoV-2 virus is an enveloped β coronavirus
that is thought to have transmitted to humans via zoonotic transfer.5,6 Virus binding and cell entry are facilitated
by a type I membrane spike glycoprotein on the surface
of the SARS-CoV-2 virus that binds to ACE (angiotensin-converting enzyme)-2 receptors found in the upper
and lower human respiratory tract.7,8 The SARS-CoV-2
virus emerged from China in December of 2019 and has
subsequently resulted in an explosion of proposed therapies for treating the virus. Among these therapies, chloroquine/hydroxychloroquine with and without azithromycin
are now commonly being used, following studies that
showed virus-cell fusion inhibition.2,3 To date, there has
been little actionable clinical data on the efficacy of using
these medications in humans infected with the SARSCoV-2 virus. In a 2005 cohort of 23 hospitalized patients
with SARS-CoV, To et al9 reported a direct correlation
between viral load and increasing age, suggesting an
increased expression of ACE-2 receptors with age may
result in higher viral loads. The relationship between viral
load and disease severity, however, was not addressed.
Viral load was noted to peak during the first week of

Figure 2. Percentage of patients with
increase in corrected QT interval
(QTc) for HCQ monotherapy vs
hydroxychloroquine and azithromycin
combination therapy.
The majority of patients in both groups
had an increase in QTc of 0–20 ms.
Higher percentage of patients treated with
the combination therapy had an increase
in QTc of 40–60 ms and >60 ms.
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Table 5.
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Characteristics of Patients With QTc >500 ms
QTc >500 ms in QTc >500 ms in
Patients Treated Patients Treated
With HCQ/CQ With HCQ/CQ and
(n=7)
AZM (n=11)
P Value

Female sex

3

3

0.63

Structural heart disease

1

0

0.39

Cirrhosis
Baseline QTc, ms

0

0

1.00

456.5±21.2

449.7±24.4

0.578

3

7

0.63

Receiving other QTprolonging medications

AZM indicates azithromycin; CQ, chloroquine; HCQ, hydroxychloroquine; and
QTc, corrected QT.

illness and steadily declined over the following week.10
Subsequently, a 30-patient study in mildly symptomatic
patients showed no benefit of chloroquine with regards
to clearance of viral load, time to temperature normalization, and disease progression.11 Major trials evaluating
clinical efficacy of this combination therapy are currently
underway globally.
A major concern with the use of this therapy has
been the risk of QT prolongation and TdP. TdP is a form
of polymorphic ventricular tachycardia that occurs in
the setting of QT prolongation that is characterized by
gradual twisting and amplitude change of the QRS complexes around an isoelectric line that either spontaneously terminates or degenerates to ventricular fibrillation
in about 10% of cases.12,13 Traditionally, QT-prolonging
agents have been avoided in individuals with a QTc >500
ms due to a 2-fold to 3-fold increase in risk for TdP with
such intervals.14–16 Most drugs cause QT prolongation by
blocking the human ether-à-go-go related gene (hERG)
potassium channel, the voltage-gated ion channel that
Table 6.

mediates the rapid component of the delayed rectifier
potassium current, I Kr, resulting in lengthening of both
ventricular repolarizations, and the duration of the ventricular action potential.17 In a similar fashion, this can
result in the reactivation of calcium influx causing triggered early afterdepolarization activity. A well-timed
early afterdepolarization trigger, in the presence of a
prolonged QT interval, can result in TdP.18
Other risk factors for TdP include drug interactions
affecting drug serum levels, concomitant use of QTprolonging agents, female sex, structural heart disease,
genetic polymorphisms, electrolyte disturbances, bradycardia, and hepatic disease. Such risk factors result in
repolarization reserve reduction.18,19 Although the QTc is
sensitive for predicting TdP, it is not specific. The relationship between QT prolongation and TdP is not linear
as drugs that prolong the QT have not consistently been
associated with cardiac arrhythmias. Incidences of sudden
cardiac death occurring in the absence of QT prolongation
on surface ECG have also been reported. Of all the QT
prolonging drugs, antiarrhythmics have the highest risk of
TdP with an incidence of 1% to 5%, whereas the risk from
noncardiovascular drugs is much lower at 0.001%.13
Four hundred million courses of antimalarial drugs
are annually used around the world.20 Antimalarial drugs
are well known for their potential cardiac toxicity and QT
prolongation effects. Of the drugs used, quinidine and
halofantrine are the most likely to cause QT prolongation and TdP.21–23 Chloroquine’s reported risk of sudden
cardiac death is limited to cases of hypotension due to
vasodilation and negative inotropy resulting from rapid
parenteral administration of the medication or situations of
self-inflicted overdose.24 The risk of QT prolongation and

Characteristics of Patients With Monomorphic Ventricular Arrhythmias
Arrhythmia
Arrhythmia Rate (beats
Duration, s per minute) CAD

Age/
sex

Medication
Regimen

49M

HCQ

240

200

0

HF

EF
(%)

Evidence of
Ischemia/
Myocarditis

1

40

Myocarditis

HS Trop,
K,
Mg, mg/ Ca2+,
mg/dL
ng/L
mmol/L
dL

Clinical
Status

4407

4.8

2.1

8.8

ICU/
ventilator

Outcome
(Length of Stay
in Days)
Deceased* (5)

58M

HCQ+AZM

5.6

180

0

1

15

No

57

3.5

2.0

8.7

Room air

Discharged (2)

65M

HCQ+AZM

12

195

0

0

58

No

28

3.7

2.0

9.4

Nasal
cannula

Discharged (14)

85M

HCQ+AZM

10

190

0

0

…

No

44

4.0

2.9

8.4

ICU/
ventilator

Deceased* (22)

56F

HCQ+AZM

5

170

0

0

…

No

67

5.5

2.7

10.1

ICU/
ventilator

Admitted (24)

88F

HCQ+AZM

20

210

0

0

…

No

50

3.7

2.5

8.4

Nasal
cannula

Discharged (13)

72F†

HCQ

3.6

180

0

0

…

No

23

4.2

1.8

10.1

Nasal
cannula

Discharged (11)

69M†

HCQ+AZM

1.6

150

0

0

…

No

15

3.5

2.1

8.7

Nasal
cannula

Discharged (6)

AZM indicates azithromycin; Ca2+, calcium; CAD, coronary artery disease; EF, ejection fraction; F, female; HCQ, hydroxychloroquine; HF, heart failure; HS, high
sensitivity; ICU, intensive care unit; K, potassium; M, male; MCOT, Mobile Cardiac Outpatient Telemetry; Mg, magnesium; and Trop, troponin.
*The cause of death for these patients was multi-system organ failure.
†These patients were monitored with MCOTs. The remainder were monitored with 12-lead electrocardiograms.
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Table 7. Proportion of Patients With Max QTc That
Continued vs Discontinued Medical Therapy With
HCQ±AZM
Total Patients on
HCQ±AZM With QTc
>500 ms

Number of Patients
Whose HCQ±AZM
Was Discontinued
Due to QTc >500 ms

500–520

8

2

520–540

2

0

540–560

3

1

560–580

2

1

580–600

2

2

>600

1

1

Max QTc, ms

AZM indicates azithromycin; HCQ, hydroxychloroquine; and QTc, corrected QT
interval.

TdP with hydroxychloroquine is limited to a series of case
reports in patients with either chronic use or overdose.25–27
The reported effects of chloroquine and hydroxychloroquine on the QT interval may also be significantly
affected by the course of acute malaria. Increased sympathetic tone due to fevers, anxiety, and anorexia at the
onset of illness results in QT interval shortening. As
patients recover with medical therapy, QT interval normalizes. QT interval normalization on day 3 of therapy,
which coincides with peak drug level, may have been
mistakenly attributed to the drugs.24 Furthermore, the
Bazett formula, used in malaria studies, overestimates
the number of patients with QT prolongation and could
have contributed to the reported QT prolonging effects
of chloroquine and hydroxychloroquine.28
Azithromycin, a widely utilized macrolide antibiotic, has
been reported to increase QT interval and incidence of
TdP.29–35 In a 2012 retrospective observational study, 5
days of therapy with azithromycin was found to have a
small but statistically significant increase in cardiovascular
Table 8.

death driven by sudden cardiac death. This effect did not
persist after the treatment was stopped.36 The proarrhythmic mechanism of azithromycin is thought to be due
to the drug’s ability to increase cardiac sodium current
and promote intracellular sodium loading.37 However,
data are lacking to show that the increased risk of death
with azithromycin is a result of QT prolongation and TdT.
Moreover, azithromycin and chloroquine combination
therapy has been used for the protection against malaria
and sexually transmitted infections in pregnant women
with no reports of syncope or sudden cardiac death.38
Our study revealed that in the entire cohort treated
with chloroquine/hydroxychloroquine or azithromycin,
the increase in QTc to its peak (max QTc), and posttreatment QTc (final QTc) were statistically significant
(P<0.05; Table 3). When further broken down to 2 treatment cohorts as shown in Table 4, the group treated
with the combination therapy had longer Max and Final
QTc intervals compared with the monotherapy group
(P=0.004 and P=0.002, respectively). However, it is
important to highlight that no patient had QTc prolongation that resulted in TdP. Seven patients (3.5%) needed
to discontinue the medications due to QTc prolongation.
Two additional patients were treated with intravenous
lidocaine that shortened the QTc allowing for continuation of hydroxychloroquine. The decision to discontinue
therapy was variable based on provider personal threshold and comfort. This explains why some patients with
similarly prolonged QTc intervals continued therapy.
As the volume of hospitalized COVID-19 patients
has increased throughout our health system, our ability
to monitor every patient receiving combination therapy
became limited due to the finite amount of telemetry beds
available. The use of MCOT patch monitors allowed us
to expand remote monitoring of cardiac arrhythmias and
QT prolongation in patients not on traditional telemetry.

Characteristics of Patients With Discontinued HCQ±AZM due to QT Prolongation

Age/
Sex

Medication Baseline Max
Regimen
QTc
QTc

Other QT
Prolonging
Meds

71M

HCQ+AZM

410

546

Amiodarone

1

0

…

No

29

5.0

2.5

9.2

ICU/ventilator

Deceased* (9)

47F

HCQ

442

483

Haloperidol,
Clozapine

0

0

…

No

16

3.7

1.9

8.6

Room air

Discharged (11)

49M

HCQ+AZM

471

617

…

0

0

…

No

11

3.7

2.8

9.2

ICU/ventilator

Admitted (25)

67M

HCQ+AZM

434

501 Dronedarone,
Pantoprazole

0

0

…

No

…

3.7

2.3

8.7

Nasal cannula Discharged (10)

83F

HCQ+AZM

444

588

…

1

1

30

No†
(Takotsubo)

400

4.0

2.7

9.1

ICU/ventilator Deceased* (22)

45M

HCQ+AZM

458

572

…

0

0

…

No

13

4.2

2.4

9.1

ICU/ventilator

56M‡

HCQ

469

0

0

…

No

16

3.9

2.2

8.8

Nonrebreather Discharged (14)

565 Pantoprazole

Evidence of
Ischemia/ HS Trop,
K,
Mg, mg/ Ca2+, mg/
dL
CAD HF EF, % Myocarditis ng/L mmol/L
dL

Clinical
Status

Outcome
(Length of Stay
in Days)

Admitted (24)

AZM indicates azithromycin; Ca , calcium; CAD, coronary artery disease; EF, ejection fraction; F, female; HCQ, hydroxychloroquine; HF, heart failure; HS, high
sensitivity; ICU, intensive care unit; K, potassium; M, male; MCOT, Mobile Cardiac Outpatient Telemetry; Mg, magnesium; QTc, corrected QT interval; and Trop, troponin.
*The cause of death was hypoxic respiratory failure and sepsis for both patients.
†A transthoracic echocardiogram performed during the admission showed apical and mid left ventricular hypokinesis with sparing of the basal segments.
‡This was the only patient that monitored with an MCOT. The remainder were monitored with 12-lead electrocardiograms.
2+
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Table 9. Arrhythmic Events and Interventions Due to QTc
Prolongation
Arrhythmic Events and Interventions

17 (8.5%)

Nonsustained, monomorphic ventricular tachycardia

7 (3.5%)

Sustained, monomorphic ventricular tachycardia

1 (0.5%)

Torsade de pointes
Arrhythmogenic death

Figure 3. Trajectory of corrected QT interval (QTc) changes
for patients whose hydroxychloroquine (HCQ)±azithromycin
(AZM) was discontinued due to QT prolongation (n=7).
The majority of the patients that had their HCQ±AZM therapy
discontinued reached a max QTc >500 ms. Decision to discontinue
therapy was based on clinician preference.

The MCOT monitor is Food and Drug Administration–
approved for the measurement, analysis, and reporting of
QT intervals. The use of the monitor resulted in a reduction
of exposures and personal protective equipment use by
healthcare workers as the need for serial ECGs to monitor
the QT interval was eliminated in this subset of patients.
Further investigation of this combination therapy is
needed, especially given the lack of randomized controlled trials showing efficacy. Based on our experience, although patients experience QTc prolongation,
especially when combination therapy is used, the risk
of arrhythmic death or TdT were not increased. Furthermore, to date, a total of 3180 patients have received
combination hydroxychloroquine and azithromycin,
and 1181 patients received hydroxychloroquine alone
for the treatment of COVID-19 in our healthcare system. There continues to be no reports of TdT in those
patients. In short, the use of this combination therapy
for a period of 5 days may not warrant monitoring for
cardiac arrhythmias in most patients. Our Infection disease team is no longer recommending the addition of
azithromycin. Coupled with the findings in this study, we
have simplified our approach to monitoring patients on
therapy. If the baseline QTc is ≤500 ms (550 if bundle
branch block or QRS duration >120 ms) no monitoring
or serial ECGs will be required. If the baseline QTc is
>500 ms (550 if bundle branch block or QRS duration
>120 ms) on telemetry or MCOTs, no serial ECGs will
be utilized for arrhythmia and QTc monitoring. We will be
performing a prospective analysis of this approach.

N=201

New-onset atrial fibrillation

0
0

Use of lidocaine for QTc >500 ms

2 (0.9%)

Hydroxychloroquine±azithromycin discontinued due to
QTc prolongation*

7 (3.5%)

QTc indicates corrected QT interval.
*Values listed are represented as numbers (percentages) for categorical
variables.

received ≥1 of these medications during the course of
their admission during this study period. The number of
patients with underlying cardiac disease in the study is
small, potentially limiting generalizability to that population. The study is subject to the same limitations as
other observational studies. Although baseline QT interval readings on MCOT were correlated to the baseline
ECGs, subsequent QT intervals in the MCOT subset
obtained while on therapy were not. This fact and the
difference in filtering in MCOT patches versus traditional
12-lead ECG are a limitation. Over 4000 patients across
the 17 hospitals in the Northwell Health system have
received one or both therapies as of April 4, 2020 with
no reported instances of TdT. This statistic, although very
encouraging, may be subject to reporting bias. Lastly,
our cohort of 201 patients, from the initial phases of
this pandemic, represents a small fraction of the total
patients we have treated. Further work is needed to confirm our findings in an even larger group of patients.

Conclusions
This is the largest reported cohort to date of patients with
COVID-19 that were treated with chloroquine/hydroxychloroquine with and without azithromycin. We observed
a marked increase in the QT intervals of these patients
during treatment, that was more pronounced in patients
treated with combination therapy. Despite this increase,
very few patients had the medications discontinued prematurely due to QT prolongation. Most importantly, there
were no cases of torsade de pointes or arrhythmic death
in the entire population. Further study of the need for QT
interval monitoring is needed before final recommendations can be made.

Limitations
The main limitation of this study is the absence of a
control cohort of patients with COVID-19 infections
that were not treated with any of these medications.
Although this would have provided a stronger analysis, nearly every hospitalized patient with COVID-19
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